News

Read a patient safety notice announcing an Astellas Pharma recall of certain lots of immunosuppressant capsules.

Read a message from Richard Formica, M.D., the OPTN Board President, regarding organ donation process questions.

Read an update from Richard Formica, M.D., OPTN President, on the HRSA directive that calls for new OPTN data collection.

Learn about updates to bylaws and new procedures for OPTN computer system access approved by the OPTN Board of Directors.

Learn about HRSA's plans to form a Transitional Nominating Committee for a new OPTN Board of Directors and about the professional expertise it seeks.

The OPTN Board of Directors has selected Rexanah Wyse Morrissette, Esq., as the OPTN’s Interim Executive Director after a national search.

View a monitoring report from the OPTN assessing two years of data after a change in kidney allocation policy.

Read about the OPTN Board's approval of an update to transplant program outcome monitoring criteria, to increase organ usage and reduce waitlist deaths.

HRSA invites public comment on its directive calling for new data collection. Comments must be submitted on or before Jan. 3, 2025.

HRSA invites comments until Dec. 31, 2024, on proposed OPTN data collection initiatives. This notice is distinct from the HRSA data directive.